Posted inEmerging Market
Eli Lilly Targets 2027 Approval for Next-Generation Triple-Agonist Obesity Drug Retatrutide
Eli Lilly plans to seek approval for its next-generation obesity drug retatrutide by 2027 following highly successful late-stage clinical trials.
